CN111588728A - 医药组合物、石斛萃取物及医药组合物的用途 - Google Patents
医药组合物、石斛萃取物及医药组合物的用途 Download PDFInfo
- Publication number
- CN111588728A CN111588728A CN202010104701.5A CN202010104701A CN111588728A CN 111588728 A CN111588728 A CN 111588728A CN 202010104701 A CN202010104701 A CN 202010104701A CN 111588728 A CN111588728 A CN 111588728A
- Authority
- CN
- China
- Prior art keywords
- extract
- compound
- dendrobium
- beta
- tetrandrine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 26
- 229930004725 sesquiterpene Natural products 0.000 claims abstract description 24
- -1 sesquiterpene compounds Chemical class 0.000 claims abstract description 23
- 230000000694 effects Effects 0.000 claims abstract description 18
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical group C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 claims abstract 5
- 241001523681 Dendrobium Species 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 27
- 240000004638 Dendrobium nobile Species 0.000 claims description 19
- 230000002633 protecting effect Effects 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 150000004354 sesquiterpene derivatives Chemical class 0.000 claims description 6
- RYAHJFGVOCZDEI-UFFNCVEVSA-N Dendrobine Chemical compound C([C@H]1CC[C@@H]2[C@@]31C)N(C)[C@@H]3[C@H]1[C@@H](C(C)C)[C@@H]2C(=O)O1 RYAHJFGVOCZDEI-UFFNCVEVSA-N 0.000 claims 2
- RYAHJFGVOCZDEI-CZKZLRAZSA-N dendrobine Natural products O=C1O[C@@H]2[C@H](C(C)C)[C@H]1[C@H]1[C@@]3(C)[C@@H]2N(C)C[C@H]3CC1 RYAHJFGVOCZDEI-CZKZLRAZSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 28
- 230000007954 hypoxia Effects 0.000 description 24
- 229940125904 compound 1 Drugs 0.000 description 23
- 190000008478 hydrogen peroxide Chemical compound 0.000 description 15
- 239000012288 hydrogen peroxide Substances 0.000 description 15
- 230000001681 protective effect Effects 0.000 description 15
- 241000252212 Danio rerio Species 0.000 description 13
- 208000002177 Cataract Diseases 0.000 description 11
- 229940125782 compound 2 Drugs 0.000 description 11
- 239000000287 crude extract Substances 0.000 description 11
- 241001076416 Dendrobium tosaense Species 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000011901 water Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 190000014300 alcohol Chemical compound 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 229940126214 compound 3 Drugs 0.000 description 6
- 210000001328 optic nerve Anatomy 0.000 description 6
- 208000003098 Ganglion Cysts Diseases 0.000 description 5
- 208000005400 Synovial Cyst Diseases 0.000 description 5
- 229930013930 alkaloid Natural products 0.000 description 5
- 150000003797 alkaloid Chemical class 0.000 description 5
- 230000005779 cell damage Effects 0.000 description 5
- 208000037887 cell injury Diseases 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 190005947998 tetrandrine structure Chemical group 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 244000283926 Dendrobium chrysotoxum Species 0.000 description 4
- 190006181239 Dendrobium chrysotoxum Chemical compound 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 190006341959 dendrobine Chemical compound 0.000 description 4
- 229930166973 dendrobine Natural products 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 229960005375 lutein Drugs 0.000 description 4
- 235000012680 lutein Nutrition 0.000 description 4
- 190000011913 lutein Chemical compound 0.000 description 4
- 229930174870 lutein Natural products 0.000 description 4
- 239000001656 lutein Substances 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 229930028302 trans-lutein Natural products 0.000 description 4
- 229930138637 xanthophyll Natural products 0.000 description 4
- 244000030990 Dendrobium fimbriatum Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 190023136437 compound 1. Chemical compound 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 150000003254 free radical Chemical class 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 190006025781 moscatilin Chemical compound 0.000 description 3
- 229930082366 moscatilin Natural products 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- 229930028203 Acetic acid Natural products 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 241000229499 Dendrobium loddigesii Species 0.000 description 2
- 229930016994 Dendroside G Natural products 0.000 description 2
- 239000007815 EtOH Substances 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 190000011743 Oxygen Chemical compound 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 190000521501 Sephadex LH-20 Chemical compound 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000001617 acetic acid Substances 0.000 description 2
- 190000009981 acetic acid Chemical compound 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 190000008877 bibenzyl compounds Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000008081 methanol Substances 0.000 description 2
- 229930158649 methanol Natural products 0.000 description 2
- 190000022349 methanol Chemical compound 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 190000021034 penicillin Chemical compound 0.000 description 2
- 230000008832 photodamage Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 190000037669 streptomycin Chemical compound 0.000 description 2
- 229930014294 streptomycin Natural products 0.000 description 2
- 229930002158 (+)-Tetrandrine Natural products 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 190000010488 CH2OH Chemical compound 0.000 description 1
- 241000026010 Dendrobium candidum Species 0.000 description 1
- 244000269590 Dendrobium chrysanthum Species 0.000 description 1
- 244000301054 Dendrobium grandiflorum Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000756137 Hemerocallis Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 190000012353 Tris-base solution Chemical compound 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000008067 acetonitrile Substances 0.000 description 1
- 190000022320 acetonitrile Chemical compound 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000011900 formic acid Substances 0.000 description 1
- 190002392265 formic acid Chemical compound 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 190006179748 from Dendrobium nobile Chemical compound 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 229930028201 methanoic acid Natural products 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229930028542 methyl cyanide Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000008397 ocular pathology Effects 0.000 description 1
- 190000021678 para Hydrogen Chemical compound 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000003137 picrotoxane Chemical class 0.000 description 1
- 229930000741 picrotoxane Natural products 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 150000004676 polysaccharide Chemical class 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229930044538 rac-Tetrandrin Natural products 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 150000003839 salt Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 190000005203 sodium bicarbonate Chemical compound 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011650 sodium bicarbonate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008791 toxic response Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000005494 xerophthalmia Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种医药组合物、石斛萃取物及医药组合物的用途,其中,该石斛萃取物的活性成分包含有印防己毒烷型结构的倍半萜类化合物,具有护眼的功效,且本发明更进一步提供此萃取物的主要活性成分,具有医学上的价值。
Description
技术领域
本发明涉及一种用于护眼的医药组合物、一种具有护眼功效的石斛萃取物以及一种使用石斛萃取物用于制备护眼的医药组合物的用途,特别是关于一种活性成分包含有印防己毒烷型(picrotoxane)结构的倍半萜类化合物的护眼的医药组合物、一种护眼的石斛萃取物以及一种使用石斛萃取物用于制备护眼的医药组合物的用途。
背景技术
根据中国台湾中药典记载,石斛生药的基原植物包括(金钗)石斛(Dendrobiumnobile Lindl.),粉花石斛(Dendrobium loddigesii Rolfe.),黄草石斛(Dendrobium.chrysanthum Wall.ex Lindl.)、马鞭石斛(Dendrobium fimbriatumHook.)、铁皮石斛(Dendrobium officinale Kimura et Migo)、鼓槌石斛(Dendrobiumchrysotoxtum Lindl.)或黄花石斛(Dendrobium tosaense Makino)。前人有关石斛的研究报导有各式活性化合物被分离出来,其中石斛碱被认为是主要活性成分;菲类(Phenanthrene)成分具有的生物活性包括抗氧化、抗发炎、抗肿瘤等作用;倍半萜类化合物具有免疫调节作用,石斛多醣类具有护肝、免疫调节、抗肿瘤、降血压等功效;联苄化合物(bibenzyl compounds)具有抗氧化和抗肿瘤等作用。虽然石斛被指明具有清肝明目的功效,而于眼睛疾病的应用虽然近期有报道指出石斛的联苄化合物moscatilin在缺氧情况下能保护视网膜损伤。然而,moscatilin是极性较低的化合物,先前有文献报道该化合物具有细胞毒性及抗肿瘤作用,本研究也发现对视神经细胞株有毒性并不适合作为治疗眼睛疾病的医学药物。临床上目前尚未有白内障、青光眼、干眼症等疾病的有效且副作用少的药物,而石斛在传统中医如何发挥其护眼作用,其活性成分为何,尚未见有相关的明确研究方向。
发明内容
本发明提供了一种护眼的医药组合物、一种护眼的石斛萃取物以及一种使用石斛萃取物用于制备护眼的医药组合物的用途,其中一个特征在于使用印防己毒烷型结构的倍半萜类化合物作为其活性成分。
根据本发明的一实施例,本发明提供了一种具有护眼功效的石斛萃取物,该石斛萃取物的活性成分包含有印防己毒烷型结构的倍半萜类化合物。
根据本发明另一实施例,本发明提供了一种使用石斛萃取物用于制备护眼的医药组合物的用途,其中该石斛萃取物的活性成分包含有印防己毒烷型结构的倍半萜类化合物。
根据本发明又一实施例,本发明提供了一种用于护眼的医药组合物,其活性成分包含有印防己毒烷型结构的倍半萜类化合物。
本发明所获得的石斛萃取物具有护眼的功效,且本发明更进一步提供此萃取物的主要活性成分,具有医学上的价值。
附图说明
图1为本发明一种实施例石斛的酒精/水粗萃物A对人类视网膜神经细胞(ARPE-19)和大鼠视神经节细胞(RGC-5)在过氧化氢、缺氧及紫外光照射损伤下对细胞的保护作用;
图2为本发明一种实施例石斛的萃取物A-2分别对人类视网膜神经细胞(ARPE-19)和大鼠视神经节细胞(RGC-5)在过氧化氢、缺氧及紫外光照射损伤下对细胞的保护作用;
图3为本发明一种实施例石斛活性成分化合物1、化合物2、化合物3与叶黄素对过氧化氢,缺氧或紫外光照射导致的ARPE-19和RGC-5细胞损伤下对细胞的保护作用;
图4为本发明一种实施例石斛活性成分化合物1在不同浓度下,对过氧化氢,缺氧或紫外光照射导致的ARPE-19和RGC-5细胞损伤下对细胞的保护作用;
图5为本发明一种实施例石斛萃取物A-2与化合物1对斑马鱼经紫外光照射引起白内障的保护作用的量化图;
图6为本发明一种实施例石斛萃取物A-2的液相层析串联质谱(LC/MS)分析的化学剖面图。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明的一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动的前提下所获得的所有其他实施例,都属于本发明保护的范围。
下面结合附图对本发明做进一步的详细描述:
本发明是关于一种石斛萃取物,其制备方法如下。首先,提供一石斛科生药材,以60-80%乙醇/水萃取得到粗萃物A。于一实施例中,石斛科植物系指兰科石斛属(Dendrobium)植物中的(金钗)石斛(Dendrobium nobile Lindl.),但并不以此为限,于其他实施例中亦可能是铁皮石斛(Dendrobium officinale Kimura et Migo)、黄草石斛(Dendrobium chrysanthum Wall.Ex Lindl.)、马鞭石斛(Dendrobium fimbriatumHook.)、鼓槌石斛(Dendrobium chrysotoxum Lindl.)、黄花石斛(Dendrobium tosaenseMakino)或粉花石斛(Dendrobium loddigesii Rolfe.)。于一实施例中,该生药材指此石斛科植物的茎部。于一实施例中,粗萃物A占生药材的重量百分比为10~16%。
接着,利用大孔树脂进行层析,以水冲提后得到水萃取物A-1,再用40-60%乙醇/水冲提后得到另一萃取物A-2。于一实施例中,大孔树脂例如:日本三菱化工公司所开发的Diaion HP树脂系列。其中,萃取物A-2占生药材的重量百分比为3-6%。
接着,萃取物A-2先用Sephadex LH-20管柱,用甲醇溶离得富含倍半萜类成分的分划层,该部分再用制备型逆相层析管柱RP-18,以30%-45%甲醇/水做移动相,反复分离得到一系列倍半萜成分,该等活性成分为具有印防己毒烷型结构的倍半萜类化合物。于一实施例中,此倍半萜类化合物可以以结构式I来表示:
,其中R1可以是H或葡萄糖基(Glc)、R2可以是H或OH、R3可以是CH3或CH2OH,R4可以是H或OH。
于本发明的一实施例中,此种具有结构式I的化合物为dendromoniliside D(以下称化合物1),其化学式为2β,3β,11,12-tetrahydroxypicrotoxan-3(15)-olide 11-O-β-D-glucopyranoside(IUPAC命名:
1S,4S,5S,5R,6R,9S)-5-hydroxy-9-(2-hydroxypropan-2-yl)-5α-methyl-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-methyl)octahydro-2H-1,4-methanocyclopenta[d]oxepin-2-one),
其可由下方结构式II来表示:
于本发明另一实施例中,此种具有结构式I的化合物为dendrodensiflorol(以下称化合物2),其化学式为2β,3β,11,12-tetrahydroxypicrotoxan-3(15)-olide(IUPAC命名:
(1S,4S,5S,5R,6R,9S)-5-hydroxy-6-(hydroxymethyl)-9-(2-hydroxypropan-2-yl)-5α-methyloctahydro-2H-1,4-methanocyclopenta[d]oxepin-2-one),其可由下方结构式III来表示:
于本发明另一实施例中,此种具有结构式I的化合物为dendronobiloliside A(以下称化合物4),其化学式为2β,3β,11,13-tetrahydroxypicrotoxan-3(15)-olide 11-O-β-D-glucopyranoside(IUPAC命名(1S,4S,5S,5R,6R,9S)-5-hydroxyl-9-((S)-1-hydroxypropan-2-yl)-5-methyl-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2H-pyran-2-yl)-oxy)methyl)octahydro-2H-1,4-methanocyclopenta[d]oxepin-2-one),其可由下方结构式IV来表示:
于本发明另一实施例中,此种具有结构式I的化合物为dendroside G(以下称化合物7),其化学式为2β,3β,4,11-tetrahydroxypicrotoxan-3(15)-olide 11-O-β-D-glucopyranoside(IUPAC命名:
(1S,4R,5S,5αR,6R,9R)-5,9-dihydroxy-9-isopropyl-5α-methyl-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxy-methyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)octahydro-2H-1,4-methanocyclopenta[d]oxepin-2-one),其可由下方结构式V来表示:
于本发明的一实施例中,具有结构式I的活性成分可以包含上述化合物1、化合物2、化合物4或化合物7,其中之一、其中之二、其中之三或全部。于本发明较佳实施例中,活性成分是包含化合物1与化合物2,且化合物1的含量大于化合物2的含量,例如化合物1与化合物2在萃取物中的含量比例为3:1~10:1。于一实施例中,具有结构式I的活性成分占萃取物A-2的重量百分比为12~20%。
于本发明的一实施例中,萃取物A-2进一步包含有一生物碱。于一实施例中,生物碱可以以结构式VI来表示:
于一实施例中,此生物碱例如是石斛碱(dendrobine)(R=H)(以下称化合物3)、N-甲基石斛碱(N-methyldendrobinium)(R=CH3)(以下称化合物5)或N-异戊烯基石斛碱(N-isopentenyl dendrobinium)(R=isopentenyl)(以下称化合物6)。于一实施例中,生物碱占萃取物A-2的重量百分比为20~35%。
后续,将萃取物A、萃取物A-1、萃取物A-2以及活性成分(具有印防己毒烷型结构的倍半萜类化合物)分别进行人类视网膜神经细胞(ARPE-19)和大鼠视神经节细胞(RGC-5)经过氧化氢或缺氧或紫外光照射引起的视神经细胞损伤的生物活性评估,其中粗萃物A、萃取物A-2及活性成分具护眼功效,活性成分中的化合物1(dendromoniliside D)与化合物2(dendrodensiflorol)具有显著的护眼功效。本发明所称的护眼功效,指具有保护视神经细胞、活化视神经细胞或延迟视神经细胞老化或死亡的功效。更具体而言,石斛植物萃取物中的活性成分,是减少自由基、缺氧(hypoxia)或紫外线(UV)损伤导致的眼睛疾病如白内障、视网膜及黄斑部病变和青光眼的发生。以下针对前述石斛萃取物以及其中的活性成分制备方法,以及所得的萃取物具有护眼功效的实验,描述如下。
实验方法
(一)成分萃取与分析
(金钗)石斛(D.nobile)地上茎切碎后,用60%酒精/水于50℃萃取过夜,萃取液经减压浓缩后得粗萃物A,之后将粗萃物A置于大孔树脂Diaion HP-20管柱,用水冲提后的冲提液浓缩得萃取物A-1,之后管柱再用30-70%酒精/水冲提,该冲提液经减压浓缩后得萃取物A-2。萃取物A-2再利用制备型逆相层析管柱Sephadex LH-20和RP-18管柱分离其中成分得纯化合物。
上述石斛萃取物A-2利用液相层析串联质谱仪(LC/MS)分析其化学剖面,请参考图6,图6所示为石斛萃取物A-2的液相层析串联质谱(LC/MS)分析的化学剖面图,可确认其中含倍半萜类成分2β,3β,11,12-tetrahydroxypicrotoxan-3(15)-olide 11-O-β-D-glucopyranoside(化合物1;dendromoniliside D)(滞留时间,16.459分);
2β,3β,11,12-tetrahydroxypicrotoxan-3(15)-olide(化合物2;dendrodensiflorol)(滞留时间,20.410分);
2β,3β,11,13-tetrahydroxypicrotoxan-3(15)-olide 11-O-β-D-glucopyranoside(化合物4;dendronobiloliside A)(滞留时间,18.375分);
2β,3β,4,11-tetrahydroxypicrotoxanpicrotoxan-3(15)-olide 11-O-β-D-glucopyranoside(化合物7;dendroside G)(滞留时间,20.767分)等,以及含有生物碱类化合物包括N-甲基石斛碱(N-methyldendrobinium)(化合物5)(滞留时间,18.633分),石斛碱(dendrobine)(化合物3)(滞留时间,19.894分)和N-异戊烯基石斛碱(N-isopentenyldendrobinium)(化合物6)(滞留时间,33.024分)等化合物。LC/MS分析条件—仪器:Shimadzu LC-2040C,LC/MS2020;分析管柱:STAR,RP-18endcapped(2μm);移动相溶剂A:乙腈;溶剂B:0.1%甲酸;分析流程:0-2分,1-5%A;2-8分,5-10%A;8-18分,10-15%A;18-20分,15%A;20-25分,15-20%A;25-30分,20-30%A;30-35分,30%A;35-40分,30-70%A;40-45分,70%A;注射量1μl;流速:0.2ml/min。
(二)视神经细胞活性试验
1.细胞株及其培养
本实验采用人类视网膜神经细胞株(ARPE-19)和大鼠视神经节细胞株(RGC-5)。ARPE-19细胞培养在DMEM-F12培养液中,内含10%胎牛血清(FBS)、0.2%碳酸氢钠及抗生素(青霉素100units/ml、链霉素100μg/ml);大鼠视神经节细胞(RGC-5),培养在DMEM培养液中,内含10%胎牛血清(FBS)及抗生素(青霉素100units/ml、链霉素100μg/ml)。
2.过氧化氢,缺氧和紫外光诱发细胞损伤的实验
ARPE-19和RGC-5细胞在过氧化氢(H2O2)或缺氧(hypoxia)或紫外光(UV)照射处理下会导致细胞死亡,细胞存活率测定:将细胞置于96-孔盘培养皿中,经过1天,再以不同浓度石斛萃取物或化合物1~4预处理24小时后,再加入过氧化氢(H2O2;500μM)或放置于缺氧环境中培养24小时或紫外光(UV;30μJ/cm2)光照,连续照三次,每次照60秒,两次中间间隔60秒后,在细胞培养箱内培养24小时,然后再用Sulforhodamine B(SRB)呈色法分析其中存活细胞:分析时,每孔加入50μl的50%TCA(即每孔含有10%TCA)用以固定细胞,置放于4℃1小时后,用二次水清洗5次,待完全干燥后,每孔加入100μl的0.4%SRB(w/v,溶于1%醋酸)染色60分钟,以1%醋酸清洗数次,待完全干燥后以10mM Tris-base溶液将SRB萃取出来,在ELISA reader测量540nm的吸光值,以未处理的控制组的吸光值当作100%细胞存活率,计算各处理的存活百分比。
3.UVC诱发斑马鱼白内障试验
斑马鱼随机分组(每组12只),分别为空白对照组、UVC(300μJ/cm2)照射组和UVC照射+给药实验组(萃取物A-2分别给予0.495,0.99和4.95mg/ml三组;化合物1分别给予0.1和1.0mM两组)。斑马鱼预先投喂石斛萃取物A-2或化合物1一个星期,再进行UVC照射,每天观察斑马鱼的水晶体变化。于UVC照射前,先将斑马鱼进行麻醉,仅让斑马鱼的眼睛露出,使其暴露于UVC(325μJ/cm2)中约3分钟,连续进行七天UV实验之后,每天观察斑马鱼眼睛的变化,斑马鱼白内障严重度依水晶体澄清的程度计分为1至等级3的白内障量化,等级越高水晶体越混浊,再以量化数值作图。
实验结果
1.石斛萃取物对过氧化氢,缺氧和紫外光照射诱发细胞损伤对ARPE-19和RGC-5细胞的保护活性
氧气经由一连串氧化作用才能提供活动所需能量,能量产生过程会制造自由基,自由基会使脂肪产生过氧化作用,甚至造成DNA、蛋白质与细胞膜的氧化伤害,所以氧气愈多的组织、能量愈高的组织,就会有所谓的“氧化压力”,而黄斑部正是人体中有高度氧化压力的组织之一。因此,氧化压力是造成许多眼睛疾病与失明的重要原因。此外,造成眼睛病变的另一个主要原因为网膜缺血,网膜缺血容易导致网膜周边细胞缺氧,因而产生细胞坏死。因此,我们建立氧化压力(H2O2)诱导及缺氧及UV光损伤的细胞模型,作为筛选护眼活性的细胞筛选。如图1与图2所示,为石斛酒精/水粗萃物A及萃取物A-2分别对RGC-5和ARPE-19细胞的过氧化氢,缺氧及紫外光照的保护作用下细胞存活率的量化图。在图1,结果是三次实验平均值±标准误差,符号表示如下,**p<0.01:与不加H2O2或Hypoxia或UV和不加粗萃物A的空白对照组比较;#p<0.05、##p<0.01:粗萃物A处理组与加H2O2或Hypoxia或UV和不加粗萃物A的对照组比较。在图2中,符号表示如下,**p<0.01:与不加H2O2或Hypoxia或UV和不加萃取物A-2的空白对照组比较;#p<0.05、##p<0.01:萃取物A-2处理组与加H2O2或Hypoxia或UV和不加萃取物A-2的对照组比较。试验结果显示金钗石斛的粗萃物A及萃取物A-2,无论对ARPC-19和RGC-5经500μM过氧化氢或在缺氧情况下或UV照射后的损伤都具有保护作用。粗萃物A在10-100μg/ml浓度下虽然三种模式都呈浓度效应,只有在100μg/ml浓度下有显著活性;而萃取物A-2不但呈浓度效应并且在50μg/ml浓度下就有显著活性,而且其保护活性高于粗萃物A。
2.石斛的成分具有细胞保护活性
如图3所示,为金钗石斛活性成分化合物1(图中显示为compound 1)、化合物2(图中显示为compound 2)、化合物3(图中显示为compound 3)与叶黄素(lutein)(图中显示为compound 4)对过氧化氢,缺氧或UV光导致的ARPE-19和RGC-5细胞损伤下细胞存活率图。在图3中,结果是三次实验平均值±标准误差,符号表示如下,**p<0.01:与不加H2O2或Hypoxia或UV和不加compound的空白对照组比较;#p<0.05、##p<0.01:compound处理组与加H2O2或Hypoxia或UV和不加compound的对照组比较。如图3所示,石斛分离的主要倍半萜纯化物化合物1在过氧化氢(H2O2),缺氧(hypoxia)和紫外光(UV)处理下,对ARPE-19和RGC-5细胞引起的损伤有保护活性,其保护活性优于叶黄素(图中显示为compound 4);另一倍半萜成分化合物2对过氧化氢(H2O2)和紫外光(UV)也具有保护作用,其保护活性与叶黄素(图中显示为compound 4)相当;反之,石斛的指标成分石斛碱(化合物3)(dendrobine,图中显示为compound 3)则不具有保护活性。如图4所示,为石斛活性成分化合物1在不同浓度下,对过氧化氢,缺氧或UV光导致的ARPE-19和RGC-5细胞损伤下细胞存活率图。在图4中,符号表示如下,**p<0.01:与不加H2O2或Hypoxia或UV和不加化合物1(compound 1)的空白对照组比较;#p<0.05、##p<0.01:化合物1处理组与加H2O2或Hypoxia或UV和不加化合物1的对照组比较。如图4所示,活性成分化合物1进一步做浓度依赖性试验,于1-10mM浓度下对过氧化氢(H2O2),缺氧(hypoxia)和紫外光(UV)对ARPE-19和RGC-5细胞引起的损伤均呈浓度依赖性保护反应,于10mM浓度下可以达到80%以上的保护活性并且未呈现毒性反应。
3.金钗石斛萃取物A-2和化合物1对UVC诱发斑马鱼白内障的保护活性
如图5所示,为金钗石斛萃取物A-2与化合物1对斑马鱼经UV光照射引起的白内障程度示意图。在图5中,符号表示如下,*:同一组试验(第四天与第七天的试验)与加UVC不加萃取物A-2或化合物1(compound 1)的对照组比较,p<0.05;**:同一组试验与加UVC不加萃取物A-2或化合物1的药物处理组比较,p<0.01。如图5所示,经UV光照没给药组于第四天就都有白内障,给与石斛萃取物A-2无论是在第四天或第七天,在0.495-4.95mg/ml浓度下,都可以明显的降低斑马鱼白内障的发生,活性成分化合物1在0.1和1.0mM浓度下也都可以显著的降低斑马鱼白内障的发生,尤其在1mM浓度下第四天几乎没有白内障的发生。
以上仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种具有护眼功效的石斛萃取物,其特征在于,该石斛萃取物的活性成分包含有印防己毒烷型结构的倍半萜类化合物。
2.根据权利要求1所述的石斛萃取物,其特征在于,其中该石斛萃取物进一步包含有石斛碱。
3.根据权利要求1所述的石斛萃取物,其特征在于,其中该印防己毒烷型结构的倍半萜类化合物包含
2β,3β,11,12-tetrahydroxypicrotoxan-3(15)-olide11-O-β-D-glucopyranoside或2β,3β,11,12-tetrahydroxypicrotoxan-3(15)-olide。
4.根据权利要求1所述的石斛萃取物,其特征在于,其中该印防己毒烷型结构化合物的倍半萜类化合物的重量百分比为12-20%。
5.根据权利要求1所述的石斛萃取物,其特征在于,其中该石斛萃取物是取自金钗石斛。
6.一种使用石斛萃取物用于制备护眼的医药组合物的用途,其特征在于,其中该石斛萃取物的活性成分包含有印防己毒烷型结构的倍半萜类化合物。
7.根据权利要求6所述的用于制备护眼的医药组合物的用途,其特征在于,其中该印防己毒烷型结构的倍半萜类化合物包含
2β,3β,11,12-tetrahydroxypicrotoxan-3(15)-olide 11-O-β-D-glucopyranoside或2β,3β,11,12-tetrahydroxypicrotoxan-3(15)-olide。
8.根据权利要求6所述的用于制备护眼的医药组合物的用途,其特征在于,其中该印防己毒烷型结构的倍半萜类化合物的重量百分比为12~20%。
9.一种用于护眼的医药组合物,其特征在于,包含有一药学上可接受的载体以及一活性成分,该活性成分包含一印防己毒烷型结构的倍半萜类化合物。
10.根据权利要求9所述的医药组合物,其特征在于,其中该印防己毒烷型结构的倍半萜类化合物包含
2β,3β,11,12-tetrahydroxypicrotoxan-3(15)-olide 11-O-β-D-glucopyranoside或2β,3β,11,12-tetrahydroxypicrotoxan-3(15)-olide。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TWTW108105682 | 2019-02-20 | ||
TW108105682A TWI723344B (zh) | 2019-02-20 | 2019-02-20 | 使用印防己毒烷型結構之倍半萜類化合物用於製備護眼的醫藥組合物的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111588728A true CN111588728A (zh) | 2020-08-28 |
CN111588728B CN111588728B (zh) | 2021-12-10 |
Family
ID=72040474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010104701.5A Active CN111588728B (zh) | 2019-02-20 | 2020-02-20 | 医药组合物、石斛萃取物及医药组合物的用途 |
Country Status (4)
Country | Link |
---|---|
US (2) | US11576918B2 (zh) |
JP (1) | JP6972064B2 (zh) |
CN (1) | CN111588728B (zh) |
TW (1) | TWI723344B (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030110527A1 (en) * | 2000-04-25 | 2003-06-12 | Kenichi Ogawa | Cell-or organ-differentiation controllers and method of controlling morphogenesis by using the same |
CN103585475A (zh) * | 2013-12-03 | 2014-02-19 | 广西浙商投资有限公司 | 铁皮石斛生榨汁治疗慢性萎缩性胃炎的药用方法 |
CN104151373A (zh) * | 2013-05-13 | 2014-11-19 | 四川万安石斛产业开发有限公司 | 一种木脂素苷类化合物及其制备方法 |
TW201628635A (zh) * | 2015-02-11 | 2016-08-16 | 漢聖製藥科技股份有限公司 | 用以改善糖尿病視網膜病變之中草藥組合物及其用途 |
CN105859671A (zh) * | 2016-04-17 | 2016-08-17 | 温州统益生物医药科技有限公司 | 一种医药用倍半萜类化合物及其制备方法 |
WO2017065602A1 (en) * | 2015-10-13 | 2017-04-20 | Ry Pharma B.V. | Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation |
CN106581446A (zh) * | 2016-12-12 | 2017-04-26 | 中国中药公司 | 石斛提取物在制备治疗干眼症药物中的应用及药物 |
WO2018008803A1 (ko) * | 2016-07-07 | 2018-01-11 | 국민대학교산학협력단 | 세스퀴테르펜 유도체의 신규한 용도 |
CN108669531A (zh) * | 2018-03-29 | 2018-10-19 | 遵义医学院 | 一种金钗石斛粉末及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7101577B2 (en) * | 2003-08-25 | 2006-09-05 | National Yang-Ming University | Extract of plant Dendrobii caulis and preparing process thereof |
US20060251739A1 (en) * | 2005-05-04 | 2006-11-09 | National Yang-Ming University | Composition and method for treating autoimmune disease and mucosal disorder |
TWI370126B (en) | 2008-12-23 | 2012-08-11 | Univ Nat Yang Ming | Biologically active extract from dendrobium plant, use thereof and process for preparing the same |
CN103520515B (zh) * | 2013-10-09 | 2015-12-23 | 上海中医药大学 | 鼓槌石斛提取物及其医药用途 |
US9186363B1 (en) | 2014-12-31 | 2015-11-17 | Peter Shepherd Parsonson | Pharmaceutical composition and method for treating age-related macular degeneration |
US20160250271A1 (en) * | 2015-02-26 | 2016-09-01 | Han Sheng Pharmtech, Inc. | Herbal composition for diabetic retinopathy |
CN104957618A (zh) * | 2015-07-06 | 2015-10-07 | 广西健宝石斛有限责任公司 | 一种铁皮石斛鱼油护眼胶囊 |
CN105669611A (zh) * | 2016-02-20 | 2016-06-15 | 杭州富阳伟文环保科技有限公司 | 一种新的环金合欢烷型倍半萜类化合物及其制备方法和医药用途 |
US10493044B1 (en) * | 2018-05-29 | 2019-12-03 | Hsiao-Ming Chao | Method for treating developmental retinal vascular disorder |
CN108635368A (zh) | 2018-07-19 | 2018-10-12 | 南京润斛堂生物科技有限公司 | 一种含有小分子石斛多糖的眼用制剂及制备方法与应用 |
-
2019
- 2019-02-20 TW TW108105682A patent/TWI723344B/zh active
- 2019-05-28 JP JP2019099390A patent/JP6972064B2/ja active Active
-
2020
- 2020-02-20 US US16/796,893 patent/US11576918B2/en active Active
- 2020-02-20 CN CN202010104701.5A patent/CN111588728B/zh active Active
-
2023
- 2023-01-10 US US18/095,493 patent/US20230142504A1/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030110527A1 (en) * | 2000-04-25 | 2003-06-12 | Kenichi Ogawa | Cell-or organ-differentiation controllers and method of controlling morphogenesis by using the same |
CN104151373A (zh) * | 2013-05-13 | 2014-11-19 | 四川万安石斛产业开发有限公司 | 一种木脂素苷类化合物及其制备方法 |
CN103585475A (zh) * | 2013-12-03 | 2014-02-19 | 广西浙商投资有限公司 | 铁皮石斛生榨汁治疗慢性萎缩性胃炎的药用方法 |
TW201628635A (zh) * | 2015-02-11 | 2016-08-16 | 漢聖製藥科技股份有限公司 | 用以改善糖尿病視網膜病變之中草藥組合物及其用途 |
WO2017065602A1 (en) * | 2015-10-13 | 2017-04-20 | Ry Pharma B.V. | Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation |
CN105859671A (zh) * | 2016-04-17 | 2016-08-17 | 温州统益生物医药科技有限公司 | 一种医药用倍半萜类化合物及其制备方法 |
WO2018008803A1 (ko) * | 2016-07-07 | 2018-01-11 | 국민대학교산학협력단 | 세스퀴테르펜 유도체의 신규한 용도 |
CN106581446A (zh) * | 2016-12-12 | 2017-04-26 | 中国中药公司 | 石斛提取物在制备治疗干眼症药物中的应用及药物 |
CN108669531A (zh) * | 2018-03-29 | 2018-10-19 | 遵义医学院 | 一种金钗石斛粉末及其应用 |
Non-Patent Citations (5)
Title |
---|
CHUNSHENG ZHAO ET AL.: "Copacamphane, Picrotoxane, and Alloaromadendrane Sesquiterpene Glycosides and Phenolic Glycosides from Dendrobium moniliforme", 《J. NAT. PROD.》 * |
CHUN-WANG MENG ET AL: "Picrotoxane sesquiterpenoids from the stems of Dendrobium nobile and their absolute configurations and angiogenesis effect", 《FITOTERAPIA》 * |
HUA FANG ET AL: "Anti-osmoticandantioxidantactivitiesofgigantolfrom Dendrobium aurantiacumvar.denneanum against cataractogenesisingalactosemic rats", 《JOURNAL OF ETHNOPHARMACOLOGY》 * |
杨涛等: "四种中草药对大鼠半乳糖性白内障防治效用的研究", 《北京医科大学学报》 * |
龙艳: "石斛抗糖性白内障有效成分的筛选及其作用靶蛋白的初步研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Also Published As
Publication number | Publication date |
---|---|
TWI723344B (zh) | 2021-04-01 |
CN111588728B (zh) | 2021-12-10 |
JP6972064B2 (ja) | 2021-11-24 |
TW202031252A (zh) | 2020-09-01 |
US20230142504A1 (en) | 2023-05-11 |
JP2020132622A (ja) | 2020-08-31 |
US20200261468A1 (en) | 2020-08-20 |
US11576918B2 (en) | 2023-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102007675B1 (ko) | 스피룰리나 추출물 제조방법, 스피룰리나 추출물을 포함하는 인지능 개선용 약학적 조성물 및 건강기능식품 | |
JP6600626B2 (ja) | 植物抽出物及び関連組成物を得るための方法 | |
JP2022024039A (ja) | キサントフィルとヒシ属植物の加工物を含有する組成物 | |
EP2324840B1 (en) | Production of caffeoylquinic acids from plant cell cultures of echinacea angustifolia | |
JP2023174959A (ja) | フラボノイド組成物 | |
JP2021080270A (ja) | キサントフィルとヒシ属植物の加工物を含有する組成物 | |
Horng et al. | Intraocular pressure-lowering effect of Cordyceps cicadae mycelia extract in a glaucoma rat model | |
CN111588728B (zh) | 医药组合物、石斛萃取物及医药组合物的用途 | |
CN108659089B (zh) | 一种具有抗氧化作用的甾醇化合物及其在制备药物中的应用 | |
KR20180054501A (ko) | 개똥쑥 추출물을 유효성분으로 포함하는 피부질환을 개선시키기 위한 조성물 및 그 제조방법 | |
US6998394B2 (en) | Process for isolating physalins from plants and pharmaceutical compositions containing physalins | |
TWI631947B (zh) | 雲芝萃取物,分離生物活性化合物之方法及其用途 | |
Lu et al. | Protective effects of Gracilaria lemaneiformis extract against ultraviolet B-induced damage in HaCaT cells | |
US20230404946A1 (en) | Use of (5r,7r,10r)-12,15-dioxo-alpha-selinene in the preparation of drugs | |
CN102558128A (zh) | 含银杏原花青素提取物及其制备方法和应用 | |
KR101866925B1 (ko) | 시링가레시놀을 포함하는 눈 질환 개선용 조성물 | |
Umaru et al. | Antidiabetic potentials of leaves extract of Barringtonia Racemosa (L) in Alloxan-induced Albino rats | |
EP1395270A1 (de) | Verwendung von phyllanthusbestandteilen zur behandlung oder prophylaxe von infekten durch hepatitis b-viren | |
US20070258989A1 (en) | Immunomodulatory pharmaceutical composition and a process for preparation thereof | |
KR20140019707A (ko) | 환삼덩굴 추출물을 유효성분으로 하는 항결핵용 조성물 | |
CN110204477B (zh) | 一种具有抗氧化作用的二萜生物碱及其在制备药物中的应用 | |
EP2199289A1 (en) | Biologically active extract from Dendrobium plant, use thereof and process for preparing the same | |
CN113185393B (zh) | 愈创木烷型倍半萜化合物、其制备方法以及其应用 | |
RU2816950C2 (ru) | Пентациклические тритерпены в лечении витилиго | |
CN112972438B (zh) | 一类来源于赤芍的木脂素化合物及其制法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |